摘要
目的观察贝伐单抗联合替莫唑胺治疗复发性脑胶质瘤患者的近期疗效和安全性。方法 2010年2月至2010年9月共18例复发性脑胶质瘤患者给予贝伐单抗联合替莫唑胺方案治疗,具体方案为：替莫唑胺150~200mg/（m2.d）,口服,d1~d5,28d为1个周期;贝伐单抗5mg/kg,每14d静脉滴注1次。至少接受2个周期化疗后评价疗效和不良反应,并记录6个月无进展生存率和6个月总生存率。结果 18例患者获PR 6例（33.3%）,SD 9例（50.0%）,PD 3例（16.7%）。6个月无进展生存率和总生存率分别为66.7%（12/18）和77.8%（14/18）。主要不良反应包括骨髓抑制和胃肠道反应,均为1~2级。结论贝伐单抗联合替莫唑胺治疗复发性脑胶质瘤近期疗效较好,不良反应可耐受,远期疗效尚需进一步观察。
Objective To evaluate the side effect and efficacy of bevacizumab combined with temozolomide for recurrent glioma prospectively.Methods From February 2010 to September 2010,18 cases of recurrent glioma were enrolled in this study.All the patients received temozolomide（150-200mg/m2,d1-d5,oral administration,28 days was a cycle） and bevacizumab（5mg/kg,iv,once for every 14 days）.Efficacy and side effects were evaluated after two cycles＇ chemotherapy.Six months＇ progression-free survival rate and overall survival rate were calculated.Results All of the 18 cases,there were 6 cases with PR（33.3%）,9 cases with SD（50.0%） and 3 cases with PD（16.7%）.The 6-month progression-free survival rate and overall survival rate were 66.7%（12/18） and 77.8%（14/18）,respectively.Myelo-suppression and gastrointestinal tract reaction were the most common toxicities,mainly 1-2 degree.Conclusion Bevacizumab combined with temozolomide is effective for recurrent glioma.The side effect is mild and tolerable.Long-term efficacy should be further observed.
出处
《临床肿瘤学杂志》
CAS
2011年第10期920-922,共3页
Chinese Clinical Oncology
作者简介
通讯作者，E—mail：dongbaijing@gmail.com
